Could a Naltrexone-Bupropion combo curb meth addiction? new trial seeks answers

NCT ID NCT06233799

Ongoing Disease control Sponsor: National Institute on Drug Abuse (NIDA) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This Phase 3 trial tests whether a combination of extended-release naltrexone (Vivitrol) and bupropion XL (Wellbutrin) can help people with moderate to severe methamphetamine use disorder reduce their drug use. About 360 participants will receive either the active drugs or placebos for 12 weeks. The main goal is to see if more participants in the drug group have at least 75% methamphetamine-negative urine tests during weeks 11-12.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: extended-release naltrexone injection (Vivitrol) and bupropion XL tablets (Wellbutrin)
What this could lead to: If successful, this could provide a new medication option to help people reduce or stop methamphetamine use, addressing a condition with no FDA-approved treatments.
What could go wrong: This is a Phase 3 trial, but previous studies have had mixed results. The combination may cause side effects like nausea or insomnia, and not everyone may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METHAMPHETAMINE ABUSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amphetamine abuse methamphetamine dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METHAMPHETAMINE ABUSE METHAMPHETAMINE-DEPENDENCE

Contacts and locations

Locations

CODA

Portland, Oregon, 97214, United States
Indiana University

Indianapolis, Indiana, 46202, United States
MUSC/BHS

Pickens, South Carolina, 29671, United States
University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States
University of California Los Angeles

Los Angeles, California, 90038, United States
University of California at San Diego

San Diego, California, 92037, United States
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States
University of Minnesota

Minneapolis, Minnesota, 55415, United States
University of Tennessee

Memphis, Tennessee, 38119, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75247, United States
University of Virginia

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.